<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5687643</article-id><article-id pub-id-type="publisher-id">21077</article-id><article-id pub-id-type="doi">10.18632/oncotarget.21077</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>A complex microsatellite at chromosome 7q33 as a new prognostic marker of colorectal cancer </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Hongyu</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Qianjin</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Duan-Fang</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Zhi-Qiang</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Deliang</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><aff id="A1"><sup>1</sup> Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China</aff><aff id="A2"><sup>2</sup> The Higher Educational Key Laboratory For Cancer Proteomics and Translational Medicine of Hunan province, Xiangya Hospital, Central South University, Changsha, Hunan 410005, China</aff><aff id="A3"><sup>3</sup> Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China</aff><aff id="A4"><sup>4</sup> Division of Stem Cell Regulation and Application, State Key Laboratory of Chinese Medicine Powder and Medicine Innovation in Hunan (incubation), Hunan University of Chinese Medicine, Changsha, Hunan 410208, China</aff></contrib-group><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Deliang Cao,</italic><email>dlcao1998@gmail.com</email></corresp><corresp id="cor2">Zhi-Qiang Xiao, <email>zqxiao2001@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><day>24</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>16</day><month>9</month><year>2017</year></pub-date><volume>8</volume><issue>51</issue><fpage>88760</fpage><lpage>88769</lpage><history><date date-type="received"><day>18</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © 2017 Ye et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Disease-specific markers are critical for early diagnosis, targeted therapy and prognostic prediction of diseases. </plain></SENT>
<SENT sid="2" pm="."><plain>Current study reports a complex microsatellite as a new prognostic marker of sporadic colorectal cancer. </plain></SENT>
<SENT sid="3" pm="."><plain>This microsatellite located at Chromosome 7q33 is composed of three tetranucleotide tandem repeats, (TTCC)2(TCCC)5(TCCT)7, flanked by a CT-rich sequence. </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed polymorphisms of this microsatellite in 158 sporadic colorectal cancer, 143 matched normal adjacent tissues (NAT) and 150 health donors. </plain></SENT>
<SENT sid="5" pm="."><plain>Our results showed that this complex microsatellite was instable with polymorphic frequency of 77.2% in colorectal cancer, 52.4% in NAT and 54.7% in health donors (p&lt;0.01) when compared to reference sequence. </plain></SENT>
<SENT sid="6" pm="."><plain>In the three tandem repeats, (TCCT)7 site was most polymorphic accounting for over 70.0% of polymorphisms in this complex microsatellite, followed by (TTCC)2 site for approximately 20%. </plain></SENT>
<SENT sid="7" pm="."><plain>Polymorphisms in (TCCC)5 was rare. </plain></SENT>
<SENT sid="8" pm="."><plain>Polymorphisms at the (TCCT)7 site were mainly insertions of 1 to 4 copies of TCCT (88.6%), and deletions occurred in about 6.4% of cases. </plain></SENT>
<SENT sid="9" pm="."><plain>The (TTCC)2 site was featured with one copy TTCC insertions. </plain></SENT>
<SENT sid="10" pm="."><plain>Pair-wise analyses between colorectal tumors and NAT revealed that 88 of 121 (72.7%) tumors displayed expansion, contraction or both in these tetranucleotide tandem repeats when compared to NAT. </plain></SENT>
<SENT sid="11" pm="."><plain>A cross-analysis with clinicopathological data of 158 colorectal cancers revealed that polymorphic alterations of the microsatellite associated with less lymphatic metastasis (p&lt;0.001), and the colorectal cancer patients with polymorphic changes in this microsatellite demonstrated better survival (n=112, p=0.0058). </plain></SENT>
<SENT sid="12" pm="."><plain>Together these data suggest that this complex microsatellite is a potential prognostic marker of sporadic colorectal cancer. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>colorectal cancer</kwd><kwd>microsatellite</kwd><kwd>polymorphisms</kwd><kwd>survival</kwd><kwd>prognostic marker</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="13" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="14" pm="."><plain>Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States; approximately 1 in 19 Americans (5.29%) will suffer from colorectal cancer during their life-time [1]. </plain></SENT>
<SENT sid="15" pm="."><plain>Individuals who have inflammatory bowel disease (IBD), i.e., ulcerative colitis and Crohn’s disease, have high risk of developing colorectal cancer, which increases exponentially with duration of the disease; surveillance of colorectal cancer in IBD patients has important clinical impact in prevention of IBD-associated cancer death [2, 3]. </plain></SENT>
</text></p><p><text><SENT sid="16" pm="."><plain>Advanced colorectal cancer has a high mortality rate; and early diagnosis is the only practical way to improve the disease-free survival of cancer patients [4–6]. </plain></SENT>
<SENT sid="17" pm="."><plain>Nearly 75% of colorectal cancer develops among people free of IBD and a familial history of hereditary non-polyposis colorectal cancer (HNPCC), colorectal neoplasia, or familial adenomatous polyposis (FAP), so called sporadic colorectal cancer. </plain></SENT>
<SENT sid="18" pm="."><plain>This makes the early diagnosis difficult due to lack of screening [7–10]. </plain></SENT>
<SENT sid="19" pm="."><plain>Up to date, colonoscopy screening in populations of IBD, FAP and HNPCC or subjects over 50 years old is an effective procedure for the surveillance and early diagnosis of colorectal cancer and has reduced the mortality in past decades [11–13]. </plain></SENT>
<SENT sid="20" pm="."><plain>However, colonoscopy is invasive and uncomfortable with potential complications, such as postpolypectomy, postbiopsy bleeding, puncturing of the colon lining and postpolypectomy syndrome [14–16]. </plain></SENT>
<SENT sid="21" pm="."><plain>Colonoscopy is also costly and requires sedation and thorough preparation of the colon, which often results in reduced patient compliance. </plain></SENT>
<SENT sid="22" pm="."><plain>Fecal occult blood test (FOBT) is non-invasive and home-based and newer methods, such as Hemoccult SENSA and fecal immunochemical tests (FIT), have improved sensitivity; however, their specificity is limited, often leading to false diagnosis [17–19]. </plain></SENT>
<SENT sid="23" pm="."><plain>In addition, FOBT fails to detect non-bleeding polyps and has poor specificity for colorectal cancer and adenoma [17, 20]. </plain></SENT>
<SENT sid="24" pm="."><plain>Hence, it is needed to identify and validate non-invasive, affordable, highly sensitive and specific biomarkers for screening and early diagnosis and/or prognostic prediction of colorectal cancer to improve the clinical management of this lethal disease. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Microsatellites have been shown to be potent genetic markers of cancers. </plain></SENT>
<SENT sid="26" pm="."><plain>Microsatellite instability (MSI) often correlates with certain age-related diseases, including colorectal cancer [21–24]. </plain></SENT>
<SENT sid="27" pm="."><plain>Microsatellites are defined as 1 to 6 repetitive DNA sequences distributed throughout the genome [25, 26]. </plain></SENT>
<SENT sid="28" pm="."><plain>MSI is a form of genomic instability that results from molecular defects in DNA mismatch repair machinery, causing frameshift mutations in highly repetitive microsatellite sequences [21, 23, 27]. </plain></SENT>
<SENT sid="29" pm="."><plain>In hereditary non-polyposis colon cancer (HNPCC), a disease caused by the mutations of DNA mismatch repair genes hMSH2 or hMLH1, MSI occurs in up to 90% of cases, compared to approximately 15% in sporadic tumors [21, 28]. </plain></SENT>
<SENT sid="30" pm="."><plain>A high level of MSI in colorectal cancer usually indicates a favorable response to adjuvant chemotherapy and better prognosis [25, 29]. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>This study found that a microsatellite located at Chromosome 7q33 functions as a prognostic marker of colorectal cancer. </plain></SENT>
<SENT sid="32" pm="."><plain>It is a complex microsatellite composed of three tetranucleotide tandem repeats, (TTCC)2(TCCC)5(TCCT)7, flanked by CT-rich sequences. </plain></SENT>
<SENT sid="33" pm="."><plain>Our results demonstrated that this complex microsatellite is instable and that its polymorphic alterations were associated with less lymph node metastasis of colorectal cancer and better patient survival. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="s2"><title><text><SENT sid="34" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec id="s2_1"><title><text><SENT sid="35" pm="."><plain>Identification of a complex repetitive sequence at Chromosome 7q33 </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>DNA sequence analysis of the AKR1B10 promoter region, a gene frequently silenced in inflammatory bowel disease and colorectal cancer [31, 32], revealed a repetitive sequence composed of tandem 4-nucleotide repeats, (TTCC)2(TCCC)5(TCCT)7, with a flanking C and T- enriched sequence (Figure 1A). </plain></SENT>
<SENT sid="37" pm="."><plain>This repetitive sequence is located at Chromosome 7 q33 (NC_000007.14, nucleotide number 134526936 - 134527095) (Figure 1B). </plain></SENT>
<SENT sid="38" pm="."><plain>In this study, we used this sequence as a reference sequence. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title><text><SENT sid="39" pm="."><plain>A complex microsatellite at Chromosome 7q33 </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>(A) Sequence and components of this microsatellite, consisting of three consecutive tetranucleotide tandem repeats flanked by a C and T- enriched sequence. (B) Diagram of the chromosomal location of this microsatellite. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-88760-g001"/></fig></SecTag></sec><sec id="s2_2"><title><text><SENT sid="41" pm="."><plain>Polymorphisms of this complex microsatellite in colorectal cancer </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>To characterize this repetitive sequence, we evaluated its polymorphisms and possible clinical implications in colorectal cancer. </plain></SENT>
<SENT sid="43" pm="."><plain>We first assessed its polymorphic changes in healthy subjects using the DNA sequence of NC_000007.14 as a reference sequence. </plain></SENT>
<SENT sid="44" pm="."><plain>Genomic DNA was amplified by PCR for conventional sequencing analysis. </plain></SENT>
<SENT sid="45" pm="."><plain>Figure 2 shows the chromatography of the sequencing data and representatives of polymorphic changes. </plain></SENT>
<SENT sid="46" pm="."><plain>Our results showed that this CT-enriched repetitive sequence is instable with polymorphic variations in 82 of 150 (54.7%) healthy donor subjects when compared to the reference sequence. </plain></SENT>
<SENT sid="47" pm="."><plain>We further analyzed the variant patterns and location in this site. </plain></SENT>
<SENT sid="48" pm="."><plain>The results showed that polymorphic variations mainly occurred in the tetranucleotide tandem repeats (TCCT)7 and (TTCC)2. </plain></SENT>
<SENT sid="49" pm="."><plain>The former accounted for 73.8% of overall polymorphic changes in this complex microsatellite and the latter denoted 24.3% of variations. </plain></SENT>
<SENT sid="50" pm="."><plain>The polymorphisms in the (TCCC)5 site were rare accounting only for 1.9% of overall polymorphisms (Table 1). </plain></SENT>
<SENT sid="51" pm="."><plain>As for the polymorphic patterns, the (TTCC)2 site was featured with insertions of a single copy TTCC, but the (TCCT)7 exhibited insertions of 1 - 4 copies of TCCT as main polymorphic forms. </plain></SENT>
<SENT sid="52" pm="."><plain>A single copy deletion of TCCT was detected in 14.6% of cases. </plain></SENT>
<SENT sid="53" pm="."><plain>A rare variant of a single copy TCTT insertion was noted in 2.9% of cases (Table 1). </plain></SENT>
<SENT sid="54" pm="."><plain>Figure 2B &amp; 2C demonstrates the representative chromatography of single copy TTCC and TCCT insertions in healthy donors. </plain></SENT>
<SENT sid="55" pm="."><plain>Figure 3A shows the representative types of polymorphisms in healthy donors. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title><text><SENT sid="56" pm="."><plain>Chromatography of this microsatellite and representative polymorphisms </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>(A) Sequencing chromatography of this microsatellite without polymorphisms, showing quality of the DNA sequencing data. (B) A sequence chromatography showing a single copy TTCC insertion. (C) A sequence chromatography showing a single copy TCCT insertion. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-88760-g002"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title><text><SENT sid="58" pm="."><plain>Microsatellite polymorphisms compared to reference sequence </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>Donors </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>NAT </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>CRC </plain></SENT>
</text></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>(n = 150) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>(n = 143) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>(n = 158) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>Polymorphic frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain> Polymorphism (%) 1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>82 (54.7) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>75 (52.4) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>122 (77.2) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain> Non-polymorphism (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>68 (45.3) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>68 (47.6) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>36 (22.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>Types and rates </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>TTCC site </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain> TTCC insertions (%)2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>25 (24.3) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>23 (23.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>36 (20.9) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>TCCC site </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain> TCCC deletions (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>2 (1.9) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>1 (1.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>8 (4.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain> TCCC insertion (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>1 (1.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>5 (2.9) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>   Subtotal (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>2 (1.9) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>2 (2.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>13 (7.6) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>TCCT site </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain> TCCT deletions (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>15 (14.6) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>12 (12.2) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>11 (6.4) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain> TCCT insertions (%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>  7 + 1 (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>15 (14.6) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>14 (14.3) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>34 (19.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>  7 + 2 (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>31 (30.1) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>25 (25.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>48 (27.9) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>  7 + 3 (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>8 (7.8) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>11 (11.2) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>22 (12.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>  7 + 4 (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>4 (3.9) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>9 (9.2) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>5 (2.9) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain> TCTT insertions (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>3 (2.9) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>2 (2.0) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>3 (1.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>   Subtotal (%)3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>76 (73.8) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>73 (74.5) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>123 (71.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>Total (PF/V)4 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>103 (1.26) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>98 (1.31) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>172 (1.41) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="127" pm="."><plain>CRC, colorectal cancer; NAT, normal adjacent tissues </plain></SENT>
</text></p><p><text><SENT sid="128" pm="."><plain>1 Subjects (percentage) with polymorphisms compared to reference sequence. p&lt;0.01, compared to NAT and donors. </plain></SENT>
</text></p><p><text><SENT sid="129" pm="."><plain>2 p&lt;0.05, compared to TCCC site. % in parenthesis indicates percentage in overall variations. </plain></SENT>
</text></p><p><text><SENT sid="130" pm="."><plain>3 p&lt;0.01, compared to TTCC and TCCC sites. </plain></SENT>
</text></p><p><text><SENT sid="131" pm="."><plain>4 PF/V, polymorphic frequency per site; more than one type of polymorphisms in some sites. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title><text><SENT sid="132" pm="."><plain>Polymorphic types of the complex microsatellite </plain></SENT>
</text></title><p><text><SENT sid="133" pm="."><plain>Presented sequences represent different types of polymorphic alterations observed in healthy donors (A), colorectal cancer (B) and normal adjacent tissues (C). </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-88760-g003"/></fig></SecTag><p><text><SENT sid="134" pm="."><plain>We further analyzed the polymorphisms of this microsatellite in 158 colorectal cancer and 143 normal adjacent colorectal tissues (NAT). </plain></SENT>
<SENT sid="135" pm="."><plain>Results showed that in the NAT samples, polymorphic frequency, types and location in this complex microsatellite were pretty similar to those in the healthy donors. </plain></SENT>
<SENT sid="136" pm="."><plain>In the colorectal cancer tissues, the variant types and spectra were also similar to those in NAT and healthy donors, but when compared to reference sequence, the polymorphic frequency was higher at 77.2% in tumors vs. 52.4% in NAT (p&lt;0.01). </plain></SENT>
<SENT sid="137" pm="."><plain>Figure 3B &amp; 3C shows the representative types of polymorphisms in colorectal cancer and normal adjacent tissues. </plain></SENT>
<SENT sid="138" pm="."><plain>The polymorphic types and rates of this complex microsatellite in colorectal cancer and normal adjacent tissues are summarized in Table 1. </plain></SENT>
<SENT sid="139" pm="."><plain>These data suggest the instability of this complex microsatellite in carcinogenic progression. </plain></SENT>
</text></p><p><text><SENT sid="140" pm="."><plain>To further address this question, we performed a pair-wise analysis of the polymorphic alterations in this microsatellite between the tumor tissues and matched NAT. </plain></SENT>
<SENT sid="141" pm="."><plain>In this study, a total of 121 pairs of colorectal specimens were collected and analyzed, and compared to the NAT, 88 (72.7%) of tumors displayed expansions, contractions or both in this complex microsatellite, suggesting that rapid cell proliferation and DNA replication during cancer development may stimulate polymorphic alterations. </plain></SENT>
<SENT sid="142" pm="."><plain>Figure 4 shows representative polymorphic variations in tumors in comparison with NAT samples. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title><text><SENT sid="143" pm="."><plain>Polymorphic variations in sporadic colorectal cancer </plain></SENT>
</text></title><p><text><SENT sid="144" pm="."><plain>DNA sequences of this complex microsatellite from paired colorectal cancer and normal adjacent specimens were subjected to paired polymorphic analyses. </plain></SENT>
<SENT sid="145" pm="."><plain>Data show that expansions, contractions or both that occurred in some tumors during tumorigenesis. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-88760-g004"/></fig></SecTag></sec><sec id="s2_3"><title><text><SENT sid="146" pm="."><plain>Negative association of the complex microsatellite polymorphisms with lymphatic metastasis of colorectal cancer </plain></SENT>
</text></title><p><text><SENT sid="147" pm="."><plain>In view of the high polymorphic variations, we further assessed the clinical significance of this complex microsatellite. </plain></SENT>
<SENT sid="148" pm="."><plain>A cross-analysis of the polymorphisms with clinicopathological parameters collected from 158 colorectal cancer was performed. </plain></SENT>
<SENT sid="149" pm="."><plain>As demonstrated in Table 2, tumors with polymorphic alterations had less lymph node metastasis (p&lt;0.001) compared to those with no polymorphic changes, suggesting its potential as a prognostic marker. </plain></SENT>
<SENT sid="150" pm="."><plain>Polymorphisms of this microsatellite had no correlation with patient age, sex or tumor size. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title><text><SENT sid="151" pm="."><plain>Correlation between microsatellite polymorphisms and clinicopathological parameters in colorectal cancer </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" colspan="1"/><th colspan="3" align="center" valign="middle" rowspan="1"><text><SENT sid="152" pm="."><plain>Colorectal Cancer (n = 158) </plain></SENT>
</text></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Polymorphisms </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Non-polymorphisms </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>P-Value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>Subtotal </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>122 (77.2) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>36 (22.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>Age (yr) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>0.8508 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain> Mean </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>60.8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>61.7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain> Median </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>65.0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>63.0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain> Range </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>23.0-89.0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>45.0-84.0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>Sex </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>0.3653 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain> Male </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>65 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>16 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain> Female </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>57 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>20 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>Tumor size (cm) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>0.8008 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain> Mean </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>5.7 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>6.1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain> Median </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>4.2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>4.5 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain> Range </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>2.3-11.8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>3.5-10.3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>Lymph node metastasis </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" style="color:#ff1a1a" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>0.0001 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain> Positive </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>35 (28.7%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>27 (75.0%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain> Negative </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>87 (71.3%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>9 (25.0%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></SecTag></sec><sec id="s2_4"><title><text><SENT sid="197" pm="."><plain>Better disease-free survival of patients with polymorphisms of this complex microsatellite </plain></SENT>
</text></title><p><text><SENT sid="198" pm="."><plain>With the finding of negative indication in lymph node metastasis, we further observed the correlation of the microsatellite instability with patient survival. </plain></SENT>
<SENT sid="199" pm="."><plain>We followed up the colorectal cancer patients subjected to the polymorphic analysis of this complex microsatellite, and survival data were obtained in 112 patients. </plain></SENT>
<SENT sid="200" pm="."><plain>Kaplan-Meier plots showed that patients with polymorphic variations of this complex microsatellite had significantly better disease-free survival (n=112, p=0.0058) (Figure 5). </plain></SENT>
<SENT sid="201" pm="."><plain>This data suggests that instability of this complex microsatellite may be a prognostic marker of colorectal cancer. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title><text><SENT sid="202" pm="."><plain>Correlation of microsatellite polymorphisms with disease-free survival of colorectal cancer patients </plain></SENT>
</text></title><p><text><SENT sid="203" pm="."><plain>Kaplan-Meier plots of patient survival were used for survival analysis. </plain></SENT>
<SENT sid="204" pm="."><plain>Data show a better survival of patients with polymorphic variations compared to those with no changes (n=112, p=0.0058). </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-88760-g005"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s3"><title><text><SENT sid="205" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="206" pm="."><plain>Colorectal cancer is a serious public health issue. </plain></SENT>
<SENT sid="207" pm="."><plain>Through decades of efforts, colorectal cancer biomarkers, including microsatellites, have contributed to the diagnosis and prognosis, as well as prediction of treatment response. </plain></SENT>
<SENT sid="208" pm="."><plain>In this study, we identified and characterized a novel microsatellite marker that is located at Chromosome 7q33. </plain></SENT>
</text></p><p><text><SENT sid="209" pm="."><plain>This microsatellite is composed of three tetranucleotide tandem repeats, (TTCC)2(TCCC)5(TCCT)7. </plain></SENT>
<SENT sid="210" pm="."><plain>Of the three different repeats, the (TCCT)7 site was most instable and accounted for majority of the polymorphic variations, followed by the (TTCC)2 while the (TCCC)5 site is virtually stable with very rare variations. </plain></SENT>
<SENT sid="211" pm="."><plain>Polymorphisms of microsatellites in tumors are often featured with expansions (insertions) and/or contractions (deletions) (27). </plain></SENT>
<SENT sid="212" pm="."><plain>Similarly, polymorphic type analyses showed that expansions or contractions were detected and that in some cases, expansions and contractions both occurred. </plain></SENT>
<SENT sid="213" pm="."><plain>However, frequency of the expansions or contractions varied. </plain></SENT>
<SENT sid="214" pm="."><plain>In the (TCCT)7 site, TCCT insertions, varied from one to four copies, were the main polymorphic forms and deletions with one copy of TCCT were a less event. </plain></SENT>
<SENT sid="215" pm="."><plain>Polymorphisms at the (TTCC)2 site were less frequent and featured with insertions of a single copy of TTCC. </plain></SENT>
<SENT sid="216" pm="."><plain>Mutations and/or epi-mutations in genes of DNA mismatch repair system (MMR), such as MLH1, MSH2, MSH6 and PMS2, leads to alterations in repeated DNA sequences (i.e., microsatellites), so-called microsatellite instability (MSI) [33]. </plain></SENT>
<SENT sid="217" pm="."><plain>However, why these tetranucleotide repeats demonstrated differential frequency of polymorphisms is currently unclear. </plain></SENT>
</text></p><p><text><SENT sid="218" pm="."><plain>Comparative analyses between healthy donors, colorectal cancers and adjacent normal tissues demonstrated that polymorphisms occurred in all three cohorts of subjects when compared to the reference sequence. </plain></SENT>
<SENT sid="219" pm="."><plain>In these specimens, the polymorphic types were similar, but the polymorphic frequency was significantly higher in the tumor tissues than in NAT and healthy donors (p&lt;0.01), indicating microsatellite instability during the tumorigenesis. </plain></SENT>
<SENT sid="220" pm="."><plain>This was further confirmed by paired analyses between colorectal cancers and matched normal adjacent tissues. </plain></SENT>
<SENT sid="221" pm="."><plain>Data showed that 72.7% of tumors displayed insertions, deletions or both in this complex microsatellite when compared to matching normal adjacent tissues. </plain></SENT>
<SENT sid="222" pm="."><plain>These data suggests that rapid cell proliferation and DNA replication during cancer development may push polymorphic alterations of this microsatellite. </plain></SENT>
</text></p><p><text><SENT sid="223" pm="."><plain>Classic microsatellite markers used clinically are monocleotide and dinucleotide repeats, and their MSI occurs in approximately 15% of sporadic colorectal cancer [33]. </plain></SENT>
<SENT sid="224" pm="."><plain>However, a specific type of MSI, named elevated microsatellite alterations at selected tetranucleotide repeats (EMAST), may occur in up to 60% of sporadic colorectal cancer [34]. </plain></SENT>
<SENT sid="225" pm="."><plain>This complex microsatellite identified here is composed of three tetranucleotide repeats, (TTCC)2(TCCC)5(TCCT)7, which may explain the high polymorphic frequency of 72.7% in total of three sites in tumors when compared to normal adjacent tissues. </plain></SENT>
<SENT sid="226" pm="."><plain>This complex microsatellite may be a new complex EMAST. </plain></SENT>
</text></p><p><text><SENT sid="227" pm="."><plain>This study also revealed that the polymorphisms of this complex microsatellite associated negatively with local lymph node metastasis, a critical factor for patient prognosis. </plain></SENT>
<SENT sid="228" pm="."><plain>This observation is consistent with literature reports that colorectal tumors with high MSI levels had less metastasis and better prognosis. </plain></SENT>
<SENT sid="229" pm="."><plain>Thus the patients with high MSI tumors have a higher disease-free survival rate compared to those without MSI [29, 35–37]. </plain></SENT>
<SENT sid="230" pm="."><plain>Indeed, a survival analysis in this study exhibited that the patients with polymorphic variations in this microsatellite had better disease-free survival, suggesting that this complex microsatellite may be a new positive prognostic marker of colorectal cancer. </plain></SENT>
<SENT sid="231" pm="."><plain>We have not a clear answer yet for decreased metastasis of the tumors with MSI, but the favorable prognosis may be ascribed to the better response to DNA damage agent 5-fluorouracil, a first-line drug for colorectal cancer. </plain></SENT>
</text></p><p><text><SENT sid="232" pm="."><plain>Stool DNA has become a useful diagnostic specimen for disease screening and diagnosis. </plain></SENT>
<SENT sid="233" pm="."><plain>For instance, stool DNA kit (PreGen-Plus, MA) is developed to detect a panel of DNA markers involved in the colorectal cancer [38, 39]. </plain></SENT>
<SENT sid="234" pm="."><plain>It may be of potential value of early diagnosis or prognosis prediction by using the developed stool DNA techniques to exam the polymorphic changes in this complex microsatellite. </plain></SENT>
<SENT sid="235" pm="."><plain>The presence of a new polymorphism in this microsatellite in the stool DNA may indicate the presence of a tumor mass or a better prognosis for patients with developed colorectal cancer. </plain></SENT>
</text></p><p><text><SENT sid="236" pm="."><plain>In summary, we identified and characterized a complex microsatellite that is located at Chromosome 7q33. </plain></SENT>
<SENT sid="237" pm="."><plain>This microsatellite has two polymorphic hot spots, (TCCT)7 and (TTCC)2, and polymorphic alterations of these spots positively associated with survival of the colorectal cancer, being a potential prognostic marker of this disease. </plain></SENT>
<SENT sid="238" pm="."><plain>A large cohort of prospective study may be merited to define the prognostic value of this microsatellite in colorectal cancer and the specificity and sensitivity of this complex microsatellite as a prognostic marker. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="s4"><title><text><SENT sid="239" pm="."><plain>MATERIALS AND METHODS </plain></SENT>
</text></title><sec id="s4_1"><title><text><SENT sid="240" pm="."><plain>Ethics statement </plain></SENT>
</text></title><p><text><SENT sid="241" pm="."><plain>IRB protocols were approved by Hunan Cancer Hospital Committee for Research Involving Human subjects. </plain></SENT>
</text></p></sec><sec id="s4_2"><title><text><SENT sid="242" pm="."><plain>Human sample procurement </plain></SENT>
</text></title><p><text><SENT sid="243" pm="."><plain>With approved IRB protocols, we procured a total of 158 sporadic colorectal cancer and 143 normal adjacent colon specimens in this study, which were surgically resected from Hunan Cancer Hospital. </plain></SENT>
<SENT sid="244" pm="."><plain>All specimens were quality-controlled by pathologists. </plain></SENT>
<SENT sid="245" pm="."><plain>Clinicopathological data, including patient age and sex, and tumor size, differentiation, and lymph node metastasis were collected. </plain></SENT>
<SENT sid="246" pm="."><plain>Normal adult genomic DNA was extracted from blood of healthy donors. </plain></SENT>
<SENT sid="247" pm="."><plain>Registered patients were followed up for 5 years of disease-free survival. </plain></SENT>
</text></p></sec><sec id="s4_3"><title><text><SENT sid="248" pm="."><plain>DNA extraction </plain></SENT>
</text></title><p><text><SENT sid="249" pm="."><plain>Genomic DNA from surgical specimens was extracted as previously described [30]. </plain></SENT>
<SENT sid="250" pm="."><plain>After being completely dissolved in TE buffer (10 mM Tris.Cl and 1 mM EDTA, pH 8.0), DNA was quantitated at 260 nm using a spectrophotometer (Beckman, CA). </plain></SENT>
</text></p></sec><sec id="s4_4"><title><text><SENT sid="251" pm="."><plain>PCR and DNA sequencing </plain></SENT>
</text></title><p><text><SENT sid="252" pm="."><plain>Genomic DNA (200 ng) were used for PCR amplification at 95°C for 45 sec, 60°C for 30 sec, and 72°C for 90 sec for 30 cycles, after an initial denature at 95°C for 5 min. </plain></SENT>
<SENT sid="253" pm="."><plain>Forward primer was 5’GAA GTA TAA GAT TTT TCA CTC ATA G, and reverse primer was 5’GAA AGG AGA ATC ACT TGA ACC T GGG. </plain></SENT>
<SENT sid="254" pm="."><plain>PCR products were purified with PCR DNA purification kit (Qiagen, CA) and the sequences were read with a nested primer (5’CAT GCC AAT TGC CTT CTA TG) by a commercial company. </plain></SENT>
</text></p></sec><sec id="s4_5"><title><text><SENT sid="255" pm="."><plain>Alignment of DNA sequences and data analysis </plain></SENT>
</text></title><p><text><SENT sid="256" pm="."><plain>Sequence chromatograms were visualized and edited using Sequencher v4.6 (Gene Codes Corporation, MI) (24). </plain></SENT>
<SENT sid="257" pm="."><plain>Edited DNA sequences were saved as text files and contigs containing all sequences for a particular group. </plain></SENT>
<SENT sid="258" pm="."><plain>Pair-wise comparisons were assembled and exported as a NEXUS file. </plain></SENT>
<SENT sid="259" pm="."><plain>The 5' end of the microsatellite was marked by a TTCT motif for alignment. </plain></SENT>
<SENT sid="260" pm="."><plain>Gaps were inserted to indicate the insertions or deletions. </plain></SENT>
<SENT sid="261" pm="."><plain>The resulting alignments were edited using MacClade v4.06 (Sinauer Associates, Inc., MA) and analyzed for polymorphic changes. </plain></SENT>
<SENT sid="262" pm="."><plain>The microsatellite and flanking sequences in the database of the National Center for Biotechnology Information were used as a reference. </plain></SENT>
</text></p></sec><sec id="s4_6"><title><text><SENT sid="263" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="264" pm="."><plain>Chi-square tests of independence, or Fisher’s exact tests when appropriate, were used to examine the relationship of microsatellite polymorphisms with tissue type, as well as with the clinical parameters of the cancer, such as gender, tumor differentiation, and lymph node metastasis. </plain></SENT>
<SENT sid="265" pm="."><plain>Analysis of variance was used to compare the polymorphism rates between sites. </plain></SENT>
<SENT sid="266" pm="."><plain>Independent group t-tests were used to assess the relationship of polymorphisms with patient age and tumor size. </plain></SENT>
<SENT sid="267" pm="."><plain>Patient survival was plotted by Kaplan-Meier analysis. </plain></SENT>
<SENT sid="268" pm="."><plain>Results were considered statistically significant with p&lt;0.05. </plain></SENT>
<SENT sid="269" pm="."><plain>All analyses were performed using SAS v9.1 software, (SAS Institute Inc., NC). </plain></SENT>
</text></p></sec></sec></SecTag></body><back><fn-group><SecTag type="AUTH_CONT"><fn fn-type="con"><p><text><SENT sid="270" pm="."><plain>Author contributions </plain></SENT>
</text></p><p><text><SENT sid="271" pm="."><plain>XY run majority of experiments, patient recruitment, data analysis and draft of the manuscript; HD assisted with experimental preparation and wet bench work; MS, QL and DH participated in the data collection and analysis; DFL aided in research design and data interpretation; DC and ZQX served in the research design, data analysis and interpretation and finalized the manuscript. </plain></SENT>
</text></p></fn></SecTag><fn fn-type="COI-statement"><p><text><SENT sid="272" pm="."><plain>CONFLICTS OF INTEREST </plain></SENT>
</text></p><p><text><SENT sid="273" pm="."><plain>Authors declare no conflicts of interest. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn fn-type="supported-by"><p><text4fund><text><SENT sid="274" pm="."><plain>FUNDING </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="275" pm="."><plain>This work was supported in part by National Natural Science Foundation of China (81472465 to DC), National Basic Research Program of China (2013CB910502; to ZQX) and the Natural Science Foundation of Guangxi Provence (2015GXNSFEA139003 to DFL). </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="R1"><text><SENT sid="276" pm="."><plain>1SiegelRLMillerKDFedewaSAAhnenDJMeesterRGBarziAJemalAColorectal cancer statistics, 2017CA Cancer J Clin20176717719328248415 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="277" pm="."><plain>2DaneseSMalesciAVetranoSColitis-associated cancer: the dark side of inflammatory bowel diseaseGut2011601609161021997561 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="278" pm="."><plain>3RoglerGChronic ulcerative colitis and colorectal cancerCancer letters201434523524123941831 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="279" pm="."><plain>4KuipersEJGradyWMLiebermanDSeufferleinTSungJJBoelensPGvan de VeldeCJWatanabeTColorectal cancerNature reviews Disease primers2015115065 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="280" pm="."><plain>5MarleyARNanHEpidemiology of colorectal cancerInternational journal of molecular epidemiology and genetics2016710511427766137 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="281" pm="."><plain>6VendrellEMoralesCRisquesRACapellaGPeinadoMAGenomic determinants of prognosis in colorectal cancerCancer letters20052211915797621 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="282" pm="."><plain>7WinawerSJSchottenfeldDFlehingerBJColorectal cancer screeningJournal of the National Cancer Institute1991832432531994053 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="283" pm="."><plain>8KolligsFTDiagnostics and Epidemiology of Colorectal CancerVisceral medicine20163215816427493942 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="284" pm="."><plain>9Pavlovic-CalicNMuminhodzicKZildzicMSmajicMGegicAAlibegovicESalkicNJovanovicPBasicMIljazovicSGenetics, clinical manifestations and management of FAP and HNPCCMedicinski arhiv20076125625918298004 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="285" pm="."><plain>10PistoriusSGorgensHPlaschkeJHoehlRKrugerSEngelCSaegerHDSchackertHKGenomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutationsCancer letters2007248899516837128 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="286" pm="."><plain>11LynchPMPrevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCCDigestion200776687617947820 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="287" pm="."><plain>12KumarASLeeJKColonoscopy: Advanced and Emerging Techniques-A Review of Colonoscopic Approaches to Colorectal ConditionsClinics in colon and rectal surgery20173013614428381945 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="288" pm="."><plain>13HazewinkelYDekkerEColonoscopy: basic principles and novel techniquesNature reviews Gastroenterology &amp; hepatology2011855456421894202 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="289" pm="."><plain>14LevinTRZhaoWConellCSeeffLCManninenDLShapiroJASchulmanJComplications of colonoscopy in an integrated health care delivery systemAnnals of internal medicine200614588088617179057 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="290" pm="."><plain>15DafnisGEkbomAPahlmanLBlomqvistPComplications of diagnostic and therapeutic colonoscopy within a defined population in SwedenGastrointestinal endoscopy20015430230911522969 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="291" pm="."><plain>16DayLWKwonAInadomiJMWalterLCSomsoukMAdverse events in older patients undergoing colonoscopy: a systematic review and meta-analysisGastrointestinal endoscopy20117488589621951478 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="292" pm="."><plain>17AndersonWFGuytonKZHiattRAVernonSWLevinBHawkEColorectal cancer screening for persons at average riskJournal of the National Cancer Institute2002941126113312165637 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="293" pm="."><plain>18SwaroopVSLarsonMVColonoscopy as a screening test for colorectal cancer in average-risk individualsMayo Clinic proceedings20027795195612233928 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="294" pm="."><plain>19RennertGKislitsinDBrennerDERennertHSLevZDetecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancerCancer letters200725325826417349741 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="295" pm="."><plain>20PotterMBStrategies and resources to address colorectal cancer screening rates and disparities in the United States and globallyAnnual review of public health201334413429 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="296" pm="."><plain>21GradyWMGenomic instability and colon cancerCancer metastasis reviews200423112715000146 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="297" pm="."><plain>22FleisherASEstellerMHarpazNLeytinARashidAXuYLiangJStineOCYinJZouTTAbrahamJMKongDWilsonKTMicrosatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1Cancer research2000604864486810987299 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="298" pm="."><plain>23WoernerSMKloorMMuellerARueschoffJFriedrichsNBuettnerRBuzelloMKienlePKnaebelHPKunstmannEPagenstecherCSchackertHKMosleinGMicrosatellite instability of selective target genes in HNPCC-associated colon adenomasOncogene2005242525253515735733 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="299" pm="."><plain>24NotarnicolaMGristinaRMessaCCariolaFFiorentePCarusoMLGentileMDi LeoAOestrogen receptors and microsatellite instability in colorectal carcinoma patientsCancer letters2001168657011368879 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="300" pm="."><plain>25ShankaranVWisinskiKBMulcahyMFBensonAB3rdThe role of molecular markers in predicting response to therapy in patients with colorectal cancerMolecular diagnosis &amp; therapy200812879818422373 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="301" pm="."><plain>26GulengGLovigTMelingGIAndersenSNRognumTOMitochondrial microsatellite instability in colorectal carcinomas--frequency and association with nuclear microsatellite instabilityCancer letters20052199710315694669 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="302" pm="."><plain>27GhimentiCTannergardPWahlbergSLiuTGiulianottiPGMoscaFFornaciariGBevilacquaGLindblomACaligoMAMicrosatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumoursBritish journal of cancer199980111610389971 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="303" pm="."><plain>28ChialinaSGFornesCLandiCde la Vega ElenaCDNicolorichMVDourisboureRJSolanoASolisEAMicrosatellite instability analysis in hereditary non-polyposis colon cancer using the Bethesda consensus panel of microsatellite markers in the absence of proband normal tissueBMC medical genetics20067516426447 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="304" pm="."><plain>29ElsalehHIacopettaBMicrosatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinomaClinical colorectal cancer2001110410912445368 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="305" pm="."><plain>30CaoDLeffertJJMcCabeJKimBPizzornoGAbnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase geneThe Journal of biological chemistry2005280211692117515772079 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="306" pm="."><plain>31ZuXYanRPanJZhongLCaoYMaJCaiCHuangDLiuJChungFLLiaoDFCaoDAldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compoundsMolecular carcinogenesis20165611812926969882 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="307" pm="."><plain>32ShenYMaJYanRLingHLiXYangWGaoJHuangCBuYCaoYHeYWanLZuXImpaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient miceClinical cancer research2015211466147625538260 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="308" pm="."><plain>33Gonzalez-PonsMCruz-CorreaMColorectal Cancer Biomarkers: Where Are We Now?BioMed research international2015201514901426106599 </plain></SENT>
</text></ref><ref id="R34"><text><SENT sid="309" pm="."><plain>34AhrendtSADeckerPADoffekKWangBXuLDemeureMJJenJSidranskyDMicrosatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancerCancer research2000602488249110811129 </plain></SENT>
</text></ref><ref id="R35"><text><SENT sid="310" pm="."><plain>35ElsalehHShannonBIacopettaBMicrosatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapyGastroenterology20011201309131011288748 </plain></SENT>
</text></ref><ref id="R36"><text><SENT sid="311" pm="."><plain>36SamowitzWSCurtinKMaKNSchafferDColemanLWLeppertMSlatteryMLMicrosatellite instability in sporadic colon cancer is associated with an improved prognosis at the population levelCancer epidemiology, biomarkers &amp; prevention200110917923 </plain></SENT>
</text></ref><ref id="R37"><text><SENT sid="312" pm="."><plain>37BruecklWMHeinzeEMilsmannCWeinAKoebnickCJungACronerRSBrabletzTGuntherKKirchnerTHahnEGHohenbergerWBeckerHReingruberBPrognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestineCancer letters200420318119014732226 </plain></SENT>
</text></ref><ref id="R38"><text><SENT sid="313" pm="."><plain>38SweetserSAhlquistDAMulti-Target Stool DNA Test: Is the Future Here?Current gastroenterology reports2016183027165404 </plain></SENT>
</text></ref><ref id="R39"><text><SENT sid="314" pm="."><plain>39KutznerNHoffmannILinkeCThienelTGrzegorczykMUrferWMartinDWindeGTraskaTHohlbachGMullerKMKuhnenCMullerONon-invasive detection of colorectal tumours by the combined application of molecular diagnosis and the faecal occult blood testCancer letters2005229334116157216 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
